Management ChangeJun 24, 2026, 06:11 AM
Takeda Appoints Julie Kim as New President & CEO
AI Summary
Takeda Pharmaceutical Company Limited announced the official appointment of Julie Kim as its Representative Director, President, and Chief Executive Officer, concluding an 18-month CEO transition. Shareholders elected Ms. Kim as a new internal director, and she was subsequently appointed to the top leadership role by the Board of Directors. Former President & CEO Christophe Weber retired from the company. Additionally, the company announced new assignments for directors, including the election of three new external directors, further strengthening corporate governance with a majority of external directors on the Board and its key committees.
Key Highlights
- Julie Kim officially appointed Takeda's Representative Director, President, and CEO.
- Shareholders elected Julie Kim as a new internal director to the Board of Directors.
- Former President & CEO Christophe Weber retired from the Company and the Board.
- Three new external directors elected: Bruce Broussard, Koichiro Kimura, and Dr. Paul Stoffels.
- Takeda's Board of Directors now comprises 8 external members out of 11 total.
- Audit and Supervisory, Nomination, and Compensation Committees will be composed solely of external directors.
Price Impact
More from TAK